Enzon Pharmaceuticals Inc. has agreed to sell its specialty pharmaceutical business to Italian-owned Sigma-Tau Pharmaceuticals Inc. for $300 million plus up to an additional $27 million based on milestones. (BioWorld Today)

Although Amgen Inc.'s Phase III Vectibix-Folfox combination met its main goal - to improve progression-free survival in patients with advanced colorectal cancer in the first-line setting - it missed its secondary endpoint of overall survival, the company reported Thursday. (BioWorld Today)

Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc. reported positive results from two pivotal Phase III trials of its bowel drug candidate linaclotide in chronic constipation. (BioWorld Today)